scholarly article | Q13442814 |
P2093 | author name string | Gonzalez FJ | |
Aoyama T | |||
Relling MV | |||
Meyer UA | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 442-447 | |
P577 | publication date | 1990-01-01 | |
P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
P1476 | title | Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily | |
P478 | volume | 252 |
Q34358861 | A screening test for slow metabolisers of tolbutamide |
Q34403343 | A study of the interaction of omeprazole and warfarin in anticoagulated patients |
Q40925106 | Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone |
Q35826971 | Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism |
Q41478156 | Clinical pharmacokinetics of tretinoin |
Q84695565 | Comparative cytotoxicity of non-steroidal anti-inflammatory drugs in primary cultures of rat hepatocytes |
Q24317436 | Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A |
Q44815207 | Cytochrome P450 2C9 phenotyping using low-dose tolbutamide |
Q24683497 | Cytochrome P4502C9: an enzyme of major importance in human drug metabolism |
Q71377766 | Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans |
Q42284671 | Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes |
Q41428950 | Drug interactions with proton pump inhibitors |
Q36350528 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance |
Q33789233 | Effects of liver disease on pharmacokinetics. An update |
Q47651375 | Effects of subacutely administered saiboku-to, an oriental herbal medicine, on pharmacodynamics and pharmacokinetics of diazepam in rodents |
Q33645193 | Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1 |
Q43790044 | Gender difference in ifosfamide metabolism by human liver microsomes |
Q36054252 | Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. |
Q34844146 | Human cytochromes P450: evolution and cDNA-directed expression |
Q36330247 | Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics |
Q34347501 | Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers—N‐desisopropylation is mediated mainly by CYP1A2 |
Q28344127 | In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6 |
Q44271677 | In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8). |
Q24550617 | Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A |
Q34983265 | Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. |
Q41073233 | Molecular basis of polymorphic drug metabolism |
Q36890310 | Omeprazole drug interaction studies |
Q35759089 | P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease |
Q40730354 | Pharmacogenetic phenotyping and genotyping. Present status and future potential. |
Q37424309 | Pharmacogenetics in diabetes |
Q41128197 | Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole |
Q43204859 | Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes |
Q42792678 | Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics |
Q41578273 | Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily |
Q43201774 | Tenidap sodium does not alter the clearance or plasma protein binding of tolbutamide in healthy male volunteers |
Q38110432 | The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs |
Search more.